Enobia has raised more than $145m from universities seed fund T2C2 (Technology, Transfer, Commercialisation, Capital) and venture capital firms.
Alexion Pharmaceuticals, a Nasdaq-listed drugs company, has agreed to buy peer Enobia Pharma for up to $1.1bn in cash from its venture consortium that includes universities fund T2C2.
Canada-based Enobia developes therapeutics for serious bone disorders and the deal includes a $610m initial payment and up to $470m in performance fees. Enobia has raised more than $145m from universities seed fund T2C2 (Technology, Transfer, Commercialisation, Capital) and venture capital firms CTI Life Sciences Fund, Desjardins Venture Capital, Kirchner Investment Management (which manages the Lothian Partners fund on behalf of Coller Capital), OrbiMed Advisors, and Solidarity Fund QFL.
Founded in 1997, Enobia raised $40m in August, two years after the $50m series C round and the C$40.1m ($40m) B round in August 2007. Data provider Crunchbase also said Enobia had raised $15.6m in 2005.
